Abstract

Prophylaxis with macrocyclic lactone (ML) endectocides is the primary strategy for heartworm control. Recent evidence has confirmed that ML-resistant Dirofilaria immitis isolates have evolved. Comparison of genomes of ML-resistant isolates show they are genetically distinct from wild-type populations. Previously, we identified single nucleotide polymorphisms (SNPs) that are correlated with phenotypic ML resistance. Since reliable in vitro assays are not available to detect ML resistance in L3 or microfilarial stages, the failure to reduce microfilaraemia in infected dogs treated with an ML has been proposed as a surrogate clinical assay for this purpose. The goal of our study was to validate the genotype-phenotype correlation between SNPs associated with ML resistance and failure to reduce microfilaraemia following ML treatment and to identify a minimal number of SNPs that could be used to confirm ML resistance. In this study, 29 participating veterinary clinics received a total of 148 kits containing supplies for blood collection, dosing and prepaid shipping. Patients recruited after a diagnosis of heartworm infection were treated with a single standard dose of Advantage Multi® and a blood sample taken pre- and approximately 2–4 weeks post-treatment. Each sample was processed by performing a modified Knott's Test followed by isolation of microfilariae, genomic DNA extraction and MiSeq sequencing of regions encompassing 10 SNP sites highly correlated with ML resistance. We observed significant correlation of SNP loci frequencies with the ML microfilaricidal response phenotype. Although all predictive SNP combination models performed well, a 2-SNP model was superior to other models tested. The predictive ability of these markers for ML-resistant heartworms should be further evaluated in clinical and epidemiological contexts.

Highlights

  • The administration of macrocyclic lactone (ML) preventive drugs is the standard of care for prophylaxis of heartworm (Dirofilaria immitis) disease in companion animals, since the introduction of ivermectin (IVM) for this indication in 1987 (Bowman and Atkins, 2009; Geary, 2005; McCall et al, 2008)

  • We have previously identified a number of single nucleotide polymorphisms (SNPs) that are highly correlated with ML resistance as defined by prophylaxis failure (Bourguinat et al, 2015, 2017a); no individual SNP identifies a single gene that accounts for the mechanism of ML resistance, a set of 4–5 SNPs is highly correlated with the phenotype (Bourguinat et al, 2017a)

  • We aimed to identify the minimal number of SNP markers that could be used for ML resistance screening in the future

Read more

Summary

Introduction

The administration of macrocyclic lactone (ML) preventive drugs is the standard of care for prophylaxis of heartworm (Dirofilaria immitis) disease in companion animals, since the introduction of ivermectin (IVM) for this indication in 1987 (Bowman and Atkins, 2009; Geary, 2005; McCall et al, 2008). Within about 20 years after the introduction of IVM, concerns about the possible emergence of drug resistance appeared; the Center for Veterinary Medicine, US Food and Drug Administration (CVM/FDA) published a report on the increasing number of lack of efficacy (LOE) claims of MLs to prevent canine heartworm disease (Hampshire, 2005) These LOE reports, wherein animals had diagnosed heartworm infection despite apparent or claimed adherence to accepted guidelines for prophylaxis, had doubled in recent years and were centered in the Lower Mississippi River delta region (Hampshire, 2005; Pulaski et al, 2014).

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.